Cytobiology and Clinical Findings of Myelodysplastic Syndromes

  • D. Hoelzer
Conference paper
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 106)

Abstract

The term preleukemia introduced by Hamilton-Paterson in 1949 and Block et al. in 1953 described any syndrome which precedes the onset of acute leukemia but in which the criteria for the diagnosis of acute leukemia are not fulfilled. Later preleukemia was considered as peripheral pancytopenia with hyperplastic bone marrow due to ineffective hemopoiesis.

Keywords

Toxicity DMSO Leukemia Anemia Oncol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Applebaum FR, Storb R, Ramberg RE, et al. (1984) Allogeneic marrow transplantation in the treatment of preleukemia. Ann Intern Med 100: 689–693Google Scholar
  2. Bagby GC Jr, Gabourel JD, Linman JW (1980) Glucocorticoid therapy in the preleukemic syndrome (hemopoietic dysplasia). Identification of responsive patients using in vitro techniques. Ann Intern Med 92: 55–58PubMedGoogle Scholar
  3. Bhadhuri S, Kubanek B, Heit W, et al. (1979) A case of preleukemia - reconstitution of normal marrow function after bone marrow transplantation ( BMT) from identical twins. Blut 38: 145–149CrossRefGoogle Scholar
  4. Bennett JM, Catovsky D, Daniel MT, et al. (1982) Proposal for the classification of the myelodysplastic syndromes. Br J Haematol 51: 189–199PubMedGoogle Scholar
  5. Bloch A (1984) Induced cell differentiation in cancer therapy. Can Treatm Rep 68: 199–205Google Scholar
  6. Block M, Jacobson LO, Bethard WF (1953) Preleukemic acute human leukemia. JAMA 152: 1018–1028CrossRefGoogle Scholar
  7. Fearon ER, Burke PJ, Schiffer CA, et al. (1986) Differentiation of leukemic cells to polymorpho-nuclear leukocytes in patients with acute nonlymphatic leukemia. N Engl J Med 315: 15–24PubMedCrossRefGoogle Scholar
  8. Francis GE, Guimaraes JETE, Berney JJ, Wing MA (1985) Synergistic interaction between differ-entiation inducers and DNA synthesis inhibitors: a new approach to differentiation induction in myelodysplasia and acute myeloid leukemia. Leuk Res 9: 573–581PubMedCrossRefGoogle Scholar
  9. Hamilton-Paterson JL (1949) Preleukaemic anaemia. Acta Haematol (Basel) 2: 309–316CrossRefGoogle Scholar
  10. Heimpel H, Hoelzer D (1982) Grenzfälle der Behandlung akuter Leukämien In: Scheurlen PG, Pees HW (eds) Aktuelle Therapie bösartiger Blutkrankheiten. Springer, Berlin Heidelberg New York, pp 58–68Google Scholar
  11. Hoelzer D, Kurrle E, Schmücker H, Harriss EB (1977) Evidence for differentiation of human leukaemic blood cells in diffusion chamber culture. Blood 49: 729–744PubMedGoogle Scholar
  12. Hoelzer G, Ganser A, Heimpel H (1984) “Atypical” leukemias: preleukemia, smoldering leukemia and hypoplastic leukemia. Recent Results Cancer Res 93: 69–101Google Scholar
  13. Hoelzer D, Ganser A, Schneider W, Heimpel H (1985) Low-dose cytosine arabinoside in the treatment of acute nonlymphoblastic leukemia and myelodysplastic syndromes. Semin Oncol [Suppl 2] 12: 208–211Google Scholar
  14. Mufti GJ, Stevens JR, Oscier DG, et al. (1985) Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 59: 425–433PubMedCrossRefGoogle Scholar
  15. Powell B, Capizzi R, Muss H, et al. (1986) Low dose Ara-C (LoDAC) treatment of acute nonlymphocytic leukemia (ANNL) and myelodysplastic syndromes ( MDS ). Proc Am Soc Clin Oncol 5: 166Google Scholar
  16. Sachs L (1978) Control of normal cell differentiation and the phenotypic reversion of malignancy in myeloid leukemia. Nature 274: 535PubMedCrossRefGoogle Scholar
  17. Schlick E, Ruscetti FW (1986) In vivo induction of terminal differentiation of malignant myelo-poietic progenitor cells by CSF-inducing biological response modifiers. Blood 67: 980–987PubMedGoogle Scholar
  18. Swanson G, Picozzi V, Morgan R, et al. (1986) Responses of hemopoietic precursors to 13-cis reti-noic acid and 1,25 dihydroxyvitamin D3 in the myelodysplastic syndromes. Blood 67: 1154–1161PubMedGoogle Scholar
  19. Teerenhovi L, Lintula R (1986) Natural course of myelodysplastic syndromes–Helsinki experi-ence. Scand J Haematol [Suppl 45] 36: 102–106CrossRefGoogle Scholar
  20. Todd WM, Pierre RV (1986) Pre-leukemia: a long-term prospective study of 326 patients. Scand J Haematol [Suppl 45] 36: 114–120CrossRefGoogle Scholar
  21. Tricot G, Bogaerts MA, Verwilghen RL (1986 a) Treatment of patients with myelodysplastic syndromes: a review. Scand J Haematol [Suppl 1] 36: 121–127Google Scholar
  22. Tricot G, Vlietinck R, Verwilghen RL (1986b) Prognostic factors in the myelodysplastic syndromes: a review. Scand J Haematol [Suppl 1] 36: 107–113CrossRefGoogle Scholar
  23. Yunis JJ, Rydell RE, Oken MM, et al. (1986) Refined chromosome analysis as an independent prognostic indicator in de novo myelodysplastic syndromes. Blood 67: 1721–1730PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1988

Authors and Affiliations

  • D. Hoelzer
    • 1
  1. 1.Abteilung für Hämatologie, Zentrum der Inneren MedizinJohann-Wolfgang-Goethe-UniversitätFrankfurt 70Germany

Personalised recommendations